The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.
EU regulators reject Leqembi for Alzheimers
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.7¢ | 2.5¢ | $53.97K | 2.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 5091747 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 6609651 | 21 |
View Market Depth
| Last trade - 14.54pm 07/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |